Medicaid

;

Nebraska Medicaid community engagement reporting requirement and people with HIV

Jan 15, 2026

We write to urge the Nebraska Medicaid program to include an explicit exemption for all people living with HIV from the community engagement reporting required under HR 1. On May 1, Nebraska intends to become the first state in the nation to implement the new community engagement requirements. People with HIV are living with a lifelong serious and complex medical condition and have special medical needs: they cannot stay healthy without continuous access to their lifesaving HIV treatment.  Any gap in treatment risks serious health consequences, including failure of viral suppression and the risk of onward transmission.

read more

Coverage of preventive services is a legal requirement

Jan 12, 2026

Carl Schmid commented on the JAMA Viewpoint piece “Subscription-Based Pricing for Lenacapavir—Learning From Hepatitis C and Cabotegravir,” taking issue with the authors’ dismissal of advocates focus on insurer’s responsibility to follow the law and cover PrEP as a no cost preventive service and offering comments on the hepatitis C subscription model and the need for a comprehensive PrEP program to increase uptake.

read more

Comments to Oregon PDAB on PBM reform, transparency, and increasing prescription drug access

Nov 14, 2025

As a national patient advocacy organization that works to promote quality and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic conditions, we see firsthand how PBM practices, pharmacy access, and insurance design determine whether patients can remain on lifesaving treatment. We appreciate the Board’s continued focus on practical, patient-centered reforms that Oregon can move forward with.

read more

Patient community concerns on CA proposal to increase minimum state rebate percentage for critical medications

Jul 11, 2025

On behalf of the HIV+Hepatitis Policy Institute and the undersigned eleven organizations committed to health equity and access to care, we write to express our deep concern regarding the Department of Health Care Services (DHCS) trailer bill proposal to increase the minimum state rebate percentage for HIV and cancer drugs. While we understand California’s fiscal challenges, we urge the Legislature to reject this proposal, which would jeopardize access to life-saving medications and disproportionately impact low- income Californians living with HIV, cancer, and other serious health conditions.

read more

Questions for Mehmet Oz, M.D. for his nomination to lead CMS

Feb 10, 2025

As the Committee considers the nomination of Mehmet C. Oz, M.D. to serve as CMS Administrator, the HIV+Hepatitis Policy Institute urges you to ensure the nominee will uphold a stalwart commitment to a comprehensive healthcare system that includes a robust private insurance market, along with strong Medicaid and Medicare programs. All are critical to making American healthier again and in ending the chronic diseases of HIV and hepatitis. Please find attached suggested questions for Dr. Oz concerning 1) a federal court decision regarding copay assistance for prescription drugs, 2) preventive services coverage under the ACA, 3) private insurance prescription drug coverage and affordability policies, and 4) the Medicare Part D six protected classes of prescription drugs.

read more

Search

Categories

Tags

340B ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest